- Home
- ENLT vs SLNO Comparison
ENLT vs SLNO Comparison
Compare ENLT & SLNO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ENLT
- SLNO
- Stock Information
- Founded
- ENLT 2008
- SLNO 1999
- Country
- ENLT Israel
- SLNO United States
- Employees
- ENLT N/A
- SLNO N/A
- Industry
- ENLT
- SLNO Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Sector
- ENLT
- SLNO Health Care
- Exchange
- ENLT Nasdaq
- SLNO Nasdaq
- Market Cap
- ENLT 2.0B
- SLNO 3.8B
- IPO Year
- ENLT 2023
- SLNO 2014
- Fundamental
- Price
- ENLT $23.74
- SLNO $82.17
- Analyst Decision
- ENLT Buy
- SLNO Strong Buy
- Analyst Count
- ENLT 3
- SLNO 9
- Target Price
- ENLT $19.67
- SLNO $103.33
- AVG Volume (30 Days)
- ENLT 43.3K
- SLNO 1.0M
- Earning Date
- ENLT 08-06-2025
- SLNO 08-06-2025
- Dividend Yield
- ENLT N/A
- SLNO N/A
- EPS Growth
- ENLT 90.47
- SLNO N/A
- EPS
- ENLT 0.98
- SLNO N/A
- Revenue
- ENLT $397,296,000.00
- SLNO N/A
- Revenue This Year
- ENLT $355.90
- SLNO N/A
- Revenue Next Year
- ENLT $42.83
- SLNO N/A
- P/E Ratio
- ENLT $24.26
- SLNO N/A
- Revenue Growth
- ENLT 44.42
- SLNO N/A
- 52 Week Low
- ENLT $14.01
- SLNO $39.41
- 52 Week High
- ENLT $23.83
- SLNO $86.79
- Technical
- Relative Strength Index (RSI)
- ENLT 73.22
- SLNO 59.70
- Support Level
- ENLT $22.61
- SLNO $82.41
- Resistance Level
- ENLT $23.72
- SLNO $86.79
- Average True Range (ATR)
- ENLT 0.47
- SLNO 2.94
- MACD
- ENLT 0.27
- SLNO 0.17
- Stochastic Oscillator
- ENLT 99.46
- SLNO 60.94
About ENLT Enlight Renewable Energy Ltd.
Enlight Renewable Energy Ltd develops, finances, constructs, owns, and operates utility-scale renewable energy projects. The company's operating segments are the MENA segment, Europe segment, U.S.A segment, and Others. It generates the majority of its revenue from the Europe segment, which produces its revenue from the sale of the electricity that is produced through wind energy and solar energy in Europe.
About SLNO Soleno Therapeutics Inc.
Soleno Therapeutics Inc is a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases. Its product candidate DCCR (Diazoxide Choline) Extended-Release tablets, is a proprietary extended-release formulation of a crystalline salt of diazoxide. DCCR has demonstrated the ability to activate the KATP channel in the brain, pancreas, and fat tissue.